Enterprise Value

3.057B

Cash

5.569M

Avg Qtr Burn

-8.955M

Short % of Float

0.01%

Insider Ownership

0.00%

Institutional Own.

13.80%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Movantik® (naloxegol) Details
Pain, Constipation, Biliary atresia, Liver disease

Approved

Quarterly sales

Approved

Quarterly sales

RHB-102 (Bekinda®) Details
Digestive tract, Stomach, Intestinal infection

Phase 3

Update

RHB-104 Details
Inflammatory disease, Crohns disease

Phase 3

Update

RHB-102 (Bekinda®) Details
Irritable bowel syndrome, Bowel disorder, Post-traumatic stress disorder, Psychiatric disorder

Phase 3

Initiation

Phase 2

Data readout

Failed

Discontinued

RHB-106 Details
Bowel preparation , Breast cancer

Failed

Discontinued

RHB-204 Details
Bacterial infection

Failed

Discontinued